Table 1 Patient characteristics by treatment group before and after PSM
| Â | Total | Entire cohort | PSM cohort | ||||
|---|---|---|---|---|---|---|---|
|  | (n = 222, %) | pre-CRT (n = 92, %) | post-CRT (n = 130, %) | p | pre-CRT (n = 60, %) | post-CRT (n = 60, %) | p |
Sex | Â | Â | Â | Â | Â | Â | Â |
 Male | 169 (76.1) | 73 (79.3) | 96 (73.8) | 0.344 | 48 (80.0) | 47 (78.3) | 0.822 |
 Female | 53 (23.9) | 19 (20.7) | 34 (26.2) |  | 12 (20.0) | 13 (21.7) |  |
Median age | 60 (27–75) | 61 (35–75) | 59 (27–75) | 0.657 | 60 (35–73) | 60 (31–75) | 0.817 |
Segment | Â | Â | Â | Â | Â | Â | Â |
 Proximal | 87 (39.2) | 57 (62.0) | 30 (23.1) | 0.000 | 31 (51.7) | 25 (41.7) | 0.171 |
 Body | 54 (24.3) | 12 (13.0) | 42 (32.3) |  | 11 (18.3) | 20 (33.3) |  |
 Distal | 81 (36.5) | 23 (25.0) | 58 (44.6) |  | 18 (30.0) | 15 (25.0) |  |
Pathological type | Â | Â | Â | Â | Â | Â | 0.103 |
 Well differentiated | 1 (0.4) | 1 (1.1) | 0 (0.0) | 0.000 | 0 (0.0) | 0 (0.0) |  |
 Moderate differentiated | 60 (27.0) | 14 (15.2) | 46 (35.4) |  | 14 (23.3) | 19 (31.7) |  |
 Poorly differentiated | 124 (55.9) | 67 (72.8) | 57 (43.8) |  | 41 (68.3) | 31 (51.7) |  |
 Mucinous adenocarcinoma | 12 (5.4) | 2 (2.2) | 10 (7.7) |  | 2 (0.3) | 5 (8.3) |  |
 Signet ring cell carcinoma | 20 (9.0) | 7 (7.6) | 13 (10.0) |  | 3 (0.5) | 5 (8.3) |  |
 Unknown | 5 (2.3) | 1 (1.1) | 4 (3.1) |  | 0 (0.0) | 0 (0.0) |  |
T stagea | Â | Â | Â | 0.000 | Â | Â | 0.691 |
 T1 | 4 (1.8) | 0 (0.0) | 4 (3.1) |  | 0 (0.0) | 0 (0.0) |  |
 T2 | 19 (8.6) | 2 (2.2) | 17 (13.1) |  | 2 (3.3) | 4 (6.7) |  |
 T3 | 106 (47.7) | 37 (40.2) | 69 (53.1) |  | 29 (48.3) | 29 (48.3) |  |
 T4 | 93 (41.9) | 53 (57.6) | 40 (30.8) |  | 29 (48.3) | 27 (45.0) |  |
N stagea | Â | Â | Â | Â | Â | Â | Â |
 N0 | 35 (15.8) | 11 (11.6) | 24 (18.5) | 0.000 | 10 (16.7) | 12 (20.0) | 0.068 |
 N1 | 49 (22.0) | 27 (29.3) | 22 (16.9) |  | 17 (28.3) | 12 (20.0) |  |
 N2 | 65 (29.3) | 36 (39.1) | 29 (22.3) |  | 21 (35.0) | 12 (20.0) |  |
 N3 | 73 (32.9) | 18 (19.6) | 55 (42.3) |  | 12 (20.0) | 24 (40.0) |  |
Surgical procedure | Â | Â | Â | Â | Â | Â | Â |
 D1 | 35 (15.8) | 9 (9.8) | 26 (20.0) | 0.000 | 9 (15.0) | 12 (20.0) | 0.332 |
 D1+ | 47 (21.2) | 17 (18.5) | 30 (23.1) |  | 12 (20.0) | 17 (28.3) |  |
 D2 | 118 (53.1) | 44 (47.8) | 74 (56.9) |  | 39 (65.0) | 31 (51.7) |  |
 No operation | 22 (9.9) | 22 (23.9) | – |  |  |  |  |
Peri-operative chemo. | Â | Â | Â | Â | Â | Â | Â |
 Yes | 194 (87.7) | 75(81.5) | 119(91.5) | 0.049 | 55(91.7) | 56(93.3) | 0.841 |
 No | 28 (12.6) | 17(18.5) | 11(8.5) |  | 5(8.3) | 4(6.7) |  |